Norway· NO-ID_39D99CDA-1642-4FCA-844B-BF454BCDE674
Tavlesse
A fostamatinib product containing fostamatinib disodium hexahydrate, registered in Norway by Instituto Grifols S.A. The same ATC class is registered in 13 of our 19 countries.
Checked against FEST (Norway) on
Informational only — not a medical device.
Where it is registered
Fostamatinib is registered in 13 of 19 countries.
Countries holding a registration under ATC B02BX09 (fostamatinib), each read from that country’s own register.
- This record: Norway, from FEST (Norway)
- 7 of them publish a price we can compare per daily dose
Fostamatinib · ATC B02BX09
13 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Japan
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
FEST (Norway)- Active substance
- Fostamatinib Disodium Hexahydrate
- Manufacturer
- Instituto Grifols S.A
- Country
- Norway (NO)
- ATC code
- B02BX09
- ATC class
- Fostamatinib
- Defined daily dose
- 0.2 g, O
- Reimbursed
- Not published by this register
- Source register
- FEST (Norway)
- Last checked
- October 2, 2026
Packs & prices · 3
1 priced- no_merkevare_idID_39D99CDA-1642-4FCA-844B-BF454BCDE674
- no_varenummer08492860NOK 74532.3
- gtin8435308344235
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
545 interactions on record for fostamatinib.
Graded by severity as the source publishes them — 50 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Fostamatinib · interactions on record
545 records
- 50 severe
- 493 moderate
- 2 minor
Most severe, free to view
- LonafarnibA16AX20severe
- BerotralstatB06AC06severe
- ConivaptanC03XA02severe
- MipomersenC10AX11severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Fostamatinib in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumTavlesse 150 mgInstituto Grifols
- CzechiaTAVLESSEInstituto Grifols, S.A., Barcelona
- SpainTAVLESSE 150 MG COMPRIMIDOS RECUBIERTOS CON PELICULAInstituto Grifols S.A.
- FinlandTavlesseInstituto Grifols S.A.
- FranceTAVLESSE 150 mg, comprimé pelliculéINSTITUTO GRIFOLS
- IrelandTavlesse 150 mg film-coated tabletsInstituto Grifols S.A.
- IcelandTAVLESSEInstituto Grifols S.A.*
- NetherlandsTavlesse 150 mg filmomhulde tablettenInstituto Grifols S.A.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Tavlesse
- Liechtenstein · Tavlesse
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FEST (Norway). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/065fd264-e76a-4230-b526-0c3c3d23f125 GET /v1/drugs/065fd264-e76a-4230-b526-0c3c3d23f125?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tablett, filmdrasjert",
"source": "fest",
"status": "A",
"atc_name": "Fostamatinib",
"merkevare_id": "ID_39D99CDA-1642-4FCA-844B-BF454BCDE674",
"name_form_strength": "Tavlesse tab 150 mg",
"prescription_group": "C"
}See everything about fostamatinib.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.